Download PDF
CC BY-NC-ND 4.0 · Journal of Clinical Interventional Radiology ISVIR 2020; 4(03): 175-183
DOI: 10.1055/s-0040-1715775
Guidelines

Indian Society of Vascular and Interventional Radiology Expert Consensus Statements for Ablation in Hepatocellular Carcinoma: Part II

Pankaj Gupta 
1   Department of Radiodiagnosis and Imaging, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Shyamkumar N. Keshava
2   Department of Interventional Radiology, Division of Clinical Radiology, Christian Medical College, Vellore, Tamil Nadu, India
,
Naveen Kalra
1   Department of Radiodiagnosis and Imaging, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Sreedhara B. Chaluvashetty
1   Department of Radiodiagnosis and Imaging, Postgraduate Institute of Medical Education and Research, Chandigarh, India
,
Amar Mukund
3   Department of Interventional Radiology, Institute of Liver and Biliary Sciences, New Delhi, India
,
Shuvro H. Roy-Choudhury
4   Department of Radiology, NH Group of Hospitals, Kolkata, West Bengal, India
,
Sanjay Saran Baijal
5   Department of Interventional Radiology, Medanta, The Medicity, Gurgaon, Haryana, India
,
Anubhav Khandelwal
5   Department of Interventional Radiology, Medanta, The Medicity, Gurgaon, Haryana, India
,
Venkatesh Hosur Ananthashayana
3   Department of Interventional Radiology, Institute of Liver and Biliary Sciences, New Delhi, India
,
Sathya Narayanan R.
2   Department of Interventional Radiology, Division of Clinical Radiology, Christian Medical College, Vellore, Tamil Nadu, India
,
Suyash S. Kulkarni
6   Department of Interventional Radiology, Tata Memorial Hospital, Mumbai, Maharashtra, India
7   Homi Bhabha National Institute, Mumbai, Maharashtra
,
Nitin Sudhakar Shetty
6   Department of Interventional Radiology, Tata Memorial Hospital, Mumbai, Maharashtra, India
7   Homi Bhabha National Institute, Mumbai, Maharashtra
,
Arun Gupta
8   Department of Interventional Radiology, Sir Ganga Ram Hospital, New Delhi, India
,
Sanjay Gupta
9   Department of Interventional Radiology, MD Anderson Cancer Center, Texas, United States
› Author Affiliations Financial Disclosures None.
› Further Information
   Permissions and Reprints

Abstract

Locoregional therapies play an important role in the management of hepatocellular carcinoma (HCC). Percutaneous ablation is one of the most commonly employed nonsurgical methods for treating very early and early HCC. For small HCC, ablation is potentially curative and competes with surgical resection. The widespread availability and the spectrum of ablative techniques mandate uniform approach among interventional radiologists. Thus, it is desirable to have a consensus regarding various aspects of the liver ablation. This article represents a consensus document of the experts from the Indian Society of Vascular and Interventional Radiology involved in the care of patients with HCC. The statements are presented in two parts.

Keywords

ablation - guidelines - RFA


Publication History

Article published online:
21 October 2020

© 2020. Indian Society of Vascular and Interventional Radiology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 White DL, Thrift AP, Kanwal F, Davila J, El-Serag HB. Incidence of hepatocellular carcinoma in all 50 United States, from 2000 through 2012. Gastroenterology 2017; 152 (04) 812-820.e5
    CrossrefPubMedGoogle Scholar
  • 2 Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 2016; 150 (04) 835-853
    CrossrefPubMedGoogle Scholar
  • 3 Heimbach JK, Kulik LM, Finn RS. et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology 2018; 67 (01) 358-380
    CrossrefPubMedGoogle Scholar
  • 4 Shiina S, Sato K, Tateishi R. et al. Percutaneous ablation for hepatocellular carcinoma: comparison of various ablation techniques and surgery. Can J Gastroenterol Hepatol 2018; 2018: 4756147
    CrossrefPubMedGoogle Scholar
  • 5 Atkins D, Best D, Briss PA. et al. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004; 328 (7454) 1490
    CrossrefPubMedGoogle Scholar
  • 6 Kang TW, Lim HK, Lee MW, Kim YS, Choi D, Rhim H. Perivascular versus nonperivascular small HCC treated with percutaneous RF ablation: retrospective comparison of long-term therapeutic outcomes. Radiology 2014; 270 (03) 888-899
    CrossrefPubMedGoogle Scholar
  • 7 de Baere T, Bessoud B, Dromain C. et al. Percutaneous radiofrequency ablation of hepatic tumors during temporary venous occlusion. AJR Am J Roentgenol 2002; 178 (01) 53-59
    CrossrefPubMedGoogle Scholar
  • 8 de Baere T, Deschamps F, Briggs P. et al. Hepatic malignancies: percutaneous radiofrequency ablation during percutaneous portal or hepatic vein occlusion. Radiology 2008; 248 (03) 1056-1066
    CrossrefPubMedGoogle Scholar
  • 9 Yamasaki T, Kurokawa F, Shirahashi H, Kusano N, Hironaka K, Okita K. Percutaneous radiofrequency ablation therapy for patients with hepatocellular carcinoma during occlusion of hepatic blood flow. Comparison with standard percutaneous radiofrequency ablation therapy. Cancer 2002; 95 (11) 2353-2360
    CrossrefPubMedGoogle Scholar
  • 10 Miyamoto N, Tsuji K, Sakurai Y. et al. Percutaneous radiofrequency ablation for unresectable large hepatic tumours during hepatic blood flow occlusion in four patients. Clin Radiol 2004; 59 (09) 812-818
    CrossrefPubMedGoogle Scholar
  • 11 Dodd III GD, Dodd NA, Lanctot AC, Glueck DA. Effect of variation of portal venous blood flow on radiofrequency and microwave ablations in a blood-perfused bovine liver model. Radiology 2013; 267 (01) 129-136
    CrossrefPubMedGoogle Scholar
  • 12 Wright AS, Sampson LA, Warner TF. Mahvi DM, Lee FT Jr. Radiofrequency versus microwave ablation in a hepatic porcine model. Radiology 2005; 236 (01) 132-139
    CrossrefPubMedGoogle Scholar
  • 13 Dou JP, Yu J, Yang XH. et al. Outcomes of microwave ablation for hepatocellular carcinoma adjacent to large vessels: a propensity score analysis. Oncotarget 2017; 8 (17) 28758-28768
    CrossrefPubMedGoogle Scholar
  • 14 Loriaud A, Denys A, Seror O. et al. Hepatocellular carcinoma abutting large vessels: comparison of four percutaneous ablation systems. Int J Hyperthermia 2018; 34 (08) 1171-1178
    CrossrefPubMedGoogle Scholar
  • 15 van Tilborg AA, Scheffer HJ, de Jong MC. et al. MWA versus RFA for perivascular and peribiliary CRLM: a retrospective patient- and lesion-based analysis of two historical cohorts. Cardiovasc Intervent Radiol 2016; 39 (10) 1438-1446
    CrossrefPubMedGoogle Scholar
  • 16 Sutter O, Calvo J, N’Kontchou G. et al. Safety and efficacy of irreversible electroporation for the treatment of hepatocellular carcinoma not amenable to thermal ablation techniques: a retrospective single-center case series. Radiology 2017; 284 (03) 877-886
    CrossrefPubMedGoogle Scholar
  • 17 Kalra N, Gupta P, Gorsi U. et al. Irreversible electroporation for unresectable hepatocellular carcinoma: initial experience. Cardiovasc Intervent Radiol 2019; 42 (04) 584-590
    CrossrefPubMedGoogle Scholar
  • 18 Bhutiani N, Philips P, Scoggins CR, McMasters KM, Potts MH, Martin RCG. Evaluation of tolerability and efficacy of irreversible electroporation (IRE) in treatment of Child-Pugh B (7/8) hepatocellular carcinoma (HCC). HPB (Oxford) 2016; 18 (07) 593-599
    CrossrefPubMedGoogle Scholar
  • 19 Cheng RG, Bhattacharya R, Yeh MM, Padia SA. Irreversible electroporation can effectively ablate hepatocellular carcinoma to complete pathologic necrosis. J Vasc Interv Radiol 2015; 26 (08) 1184-1188
    CrossrefPubMedGoogle Scholar
  • 20 Mafeld S, Wong JJ, Kibriya N. et al. Percutaneous irreversible electroporation (IRE) of hepatic malignancy: a bi-institutional analysis of safety and outcomes. Cardiovasc Intervent Radiol 2019; 42 (04) 577-583
    CrossrefPubMedGoogle Scholar
  • 21 Huang YZ, Zhou SC, Zhou H, Tong M. Radiofrequency ablation versus cryosurgery ablation for hepatocellular carcinoma: a meta-analysis. Hepatogastroenterology 2013; 60 (125) 1131-1135
    PubMedGoogle Scholar
  • 22 Wang C, Wang H, Yang W. et al. Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma. Hepatology 2015; 61 (05) 1579-1590
    CrossrefPubMedGoogle Scholar
  • 23 Kim R, Kang TW, Cha DI. et al. Percutaneous cryoablation for perivascular hepatocellular carcinoma: therapeutic efficacy and vascular complications. Eur Radiol 2019; 29 (02) 654-662
    CrossrefPubMedGoogle Scholar
  • 24 Cha SY, Kang TW, Min JH. et al. RF ablation versus cryoablation for small perivascular hepatocellular carcinoma: propensity score analyses of mid-term outcomes. Cardiovasc Intervent Radiol 2020; 43 (03) 434-444
    CrossrefPubMedGoogle Scholar
  • 25 Yoon JH, Lee EJ, Cha SS. et al. Comparison of gadoxetic acid-enhanced MR imaging versus four-phase multi-detector row computed tomography in assessing tumor regression after radiofrequency ablation in subjects with hepatocellular carcinomas. J Vasc Interv Radiol 2010; 21 (03) 348-356
    CrossrefPubMedGoogle Scholar
  • 26 Lekht I, Gulati M, Nayyar M. et al. Role of contrast-enhanced ultrasound (CEUS) in evaluation of thermal ablation zone. Abdom Radiol (NY) 2016; 41 (08) 1511-1521
    CrossrefPubMedGoogle Scholar
  • 27 Du J, Li HL, Zhai B, Chang S, Li FH. Radiofrequency ablation for hepatocellular carcinoma: utility of conventional ultrasound and contrast-enhanced ultrasound in guiding and assessing early therapeutic response and short-term follow-up results. Ultrasound Med Biol 2015; 41 (09) 2400-2411
    CrossrefPubMedGoogle Scholar
  • 28 Xu EJ, Lv SM, Li K. et al. Immediate evaluation and guidance of liver cancer thermal ablation by three-dimensional ultrasound/contrast-enhanced ultrasound fusion imaging. Int J Hyperthermia 2018; 34 (06) 870-876
    CrossrefPubMedGoogle Scholar
  • 29 Minami Y, Minami T, Hagiwara S. et al. Ultrasound-ultrasound image overlay fusion improves real-time control of radiofrequency ablation margin in the treatment of hepatocellular carcinoma. Eur Radiol 2018; 28 (05) 1986-1993
    CrossrefPubMedGoogle Scholar
  • 30 Rajesh S, Mukund A, Arora A, Jain D, Sarin SK. Contrast-enhanced US-guided radiofrequency ablation of hepatocellular carcinoma. J Vasc Interv Radiol 2013; 24 (08) 1235-1240
    CrossrefPubMedGoogle Scholar
  • 31 Rhim H, Dodd III GD. Radiofrequency thermal ablation of liver tumors. J Clin Ultrasound 1999; 27 (05) 221-229
    CrossrefPubMedGoogle Scholar
  • 32 Nguyen Q, Justaniah A, Sarwar A, Ahmed M. Does immediate peri-hepatic hematoma or contrast extravasation after hepatic tumor ablation require angiography?. J Vasc Interv Radiol 2016; 27: S125
    CrossrefPubMedGoogle Scholar
  • 33 Gao QZ, Wang ZW, Pan J, Shi HF, Zhang XB, Jin ZY. [The occurrence and clinical significance of contrast agent spillover on immediate enhanced CT reexamination after radiofrequency ablation of liver cancer]. Zhonghua Gan Zang Bing Za Zhi 2018; 26 (07) 503-507
    PubMedGoogle Scholar
  • 34 Livraghi T, Solbiati L, Meloni MF, Gazelle GS, Halpern EF, Goldberg SN. Treatment of focal liver tumors with percutaneous radio-frequency ablation: complications encountered in a multicenter study. Radiology 2003; 226 (02) 441-451
    CrossrefPubMedGoogle Scholar
  • 35 Chuang CH, Chen CY, Tsai HM. Hepatic infarction and hepatic artery pseudoaneurysm with peritoneal bleeding after radiofrequency ablation for hepatoma. Clin Gastroenterol Hepatol 2005; 3 (11) A23
    CrossrefPubMedGoogle Scholar
  • 36 Datta RV. Intrahepatic pseudoaneurysm after radiofrequency ablation of liver lesion. Int Surg 2008; 93 (06) 381-384
    PubMedGoogle Scholar
  • 37 Curley SA, Marra P, Beaty K. et al. Early and late complications after radiofrequency ablation of malignant liver tumors in 608 patients. Ann Surg 2004; 239 (04) 450-458
    CrossrefPubMedGoogle Scholar
  • 38 Akahane M, Koga H, Kato N. et al. Complications of percutaneous radiofrequency ablation for hepato-cellular carcinoma: imaging spectrum and management. Radiographics 2005; 25 (Suppl. 01) S57-S68
    CrossrefPubMedGoogle Scholar
  • 39 Vogel A, Cervantes A, Chau I. et al. Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29 (Suppl. 04) iv238-iv255
    CrossrefPubMedGoogle Scholar
  • 40 Dromain C, de Baere T, Elias D. et al. Hepatic tumors treated with percutaneous radio-frequency ablation: CT and MR imaging follow-up. Radiology 2002; 223 (01) 255-262
    CrossrefPubMedGoogle Scholar
  • 41 Lim HK, Choi D, Lee WJ. et al. Hepatocellular carcinoma treated with percutaneous radio-frequency ablation: evaluation with follow-up multiphase helical CT. Radiology 2001; 221 (02) 447-454
    CrossrefPubMedGoogle Scholar
  • 42 Liu W, Zheng Y, Zou R. et al. Impact of follow-up interval on patients with hepatocellular carcinoma after curative ablation. BMC Cancer 2018; 18 (01) 1186
    CrossrefPubMedGoogle Scholar
  • 43 Boas FE, Do B, Louie JD. et al. Optimal imaging surveillance schedules after liver-directed therapy for hepatocellular carcinoma. J Vasc Interv Radiol 2015; 26 (01) 69-73
    CrossrefPubMedGoogle Scholar
  • 44 Mikami S, Tateishi R, Akahane M. et al. Computed tomography follow-up for the detection of hepatocellular carcinoma recurrence after initial radiofrequency ablation: a single-center experience. J Vasc Interv Radiol 2012; 23 (10) 1269-1275
    CrossrefPubMedGoogle Scholar
  • 45 Granata V, Petrillo M, Fusco R. et al. Surveillance of HCC patients after liver RFA: role of MRI with hepatospecific contrast versus three-phase CT scan-experience of high volume oncologic institute. Gastroenterol Res Pract 2013; 2013: 469097
    CrossrefPubMedGoogle Scholar
  • 46 Sainani NI, Gervais DA, Mueller PR, Arellano RS. Imaging after percutaneous radiofrequency ablation of hepatic tumors: Part 2, Abnormal findings. AJR Am J Roentgenol 2013; 200 (01) 194-204
    CrossrefPubMedGoogle Scholar
  • 47 Gupta P, Kalra N, Gulati A. et al. Response assessment following image-guided therapy of hepatocellular carcinoma. J Clin Interv Radiol 2020; 4 (02) 88-97
    Article in Thieme ConnectPubMedGoogle Scholar
  • 48 Mohamed RE, Amin MA, Omar HM. Apparent diffusion coefficient and dynamic contrast-enhanced MRI as reliable biomarkers for evaluating response to locoregional therapy in hepatocellular carcinoma patients. Egypt J Radiol Nucl Med. 2018; 49: 914-927
    CrossrefPubMedGoogle Scholar
  • 49 Mahmoud BEMH, Elkholy SF, Nabeel MM. et al. Role of MRI in the assessment of treatment response after radiofrequency and microwave ablation therapy for hepatocellular carcinoma. Egypt J Radiol Nucl Med 2016; 47: 377-385
    CrossrefPubMedGoogle Scholar
  • 50 Anderson GS, Brinkmann F, Soulen MC, Alavi A, Zhuang H. FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Clin Nucl Med 2003; 28 (03) 192-197
    CrossrefPubMedGoogle Scholar
  • 51 Chaudhry M, McGinty KA, Mervak B. et al. The LI-RADS version 2018 MRI treatment response algorithm: evaluation of ablated hepatocellular carcinoma. Radiology 2020; 294 (02) 320-326
    CrossrefPubMedGoogle Scholar
  • 52 Seo N, Kim MS, Park MS. et al. Evaluation of treatment response in hepatocellular carcinoma in the explanted liver with liver imaging reporting and data system version 2017. Eur Radiol 2020; 30 (01) 261-271
    CrossrefPubMedGoogle Scholar
  • 53 Liao WJ, Shi M, Chen JZ, Li AM. Local recurrence of hepatocellular carcinoma after radiofrequency ablation. World J Gastroenterol 2010; 16 (40) 5135-5138
    CrossrefPubMedGoogle Scholar
  • 54 Chan AC, Chan SC, Chok KS. et al. Treatment strategy for recurrent hepatocellular carcinoma: salvage transplantation, repeated resection, or radiofrequency ablation?. Liver Transpl 2013; 19 (04) 411-419
    CrossrefPubMedGoogle Scholar
  • 55 Kalra N, Gupta P, Chawla Y, Khandelwal N. Locoregional treatment for hepatocellular carcinoma: the best is yet to come. World J Radiol 2015; 7 (10) 306-318
    CrossrefPubMedGoogle Scholar
  • 56 Ni JY, Liu SS, Xu LF, Sun HL, Chen YT. Meta-analysis of radiofrequency ablation in combination with transarterial chemoembolization for hepatocellular carcinoma. World J Gastroenterol 2013; 19 (24) 3872-3882
    CrossrefPubMedGoogle Scholar
  • 57 Peng ZW, Zhang YJ, Chen MS. et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol 2013; 31 (04) 426-432
    CrossrefPubMedGoogle Scholar
  • 58 Abdelaziz AO, Abdelmaksoud AH, Nabeel MM. et al. Transarterial chemoembolization combined with either radiofrequency or microwave ablation in management of hepatocellular carcinoma. Asian Pac J Cancer Prev 2017; 18 (01) 189-194
    Google Scholar
  • 59 Song MJ, Bae SH, Lee JS. et al. Combination transarterial chemoembolization and radiofrequency ablation therapy for early hepatocellular carcinoma. Korean J Intern Med (Korean Assoc Intern Med) 2016; 31 (02) 242-252
    CrossrefPubMedGoogle Scholar
  • 60 Chen QF, Jia ZY, Yang ZQ, Fan WL, Shi HB. Transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-microwave ablation therapy for hepatocellular carcinoma tumors≤5 cm: a propensity analysis at a single center. Cardiovasc Intervent Radiol 2017; 40 (11) 1748-1755
    CrossrefPubMedGoogle Scholar
  • 61 Kamal A, Barakat E, ElMoez A, Mawad M, El-Fouly N, Shaker M. Combined radiofrequency and chemoembolization vs. chemoembolization in management of hepatocellular carcinoma. Hepatoma Res 2015; 1: 19-23
    CrossrefPubMedGoogle Scholar
  • 62 Xu RC, Liu HC, Li JL. et al. Long-term outcome of transcatheter arterial chemoembolization after radiofrequency ablation as a combined therapy for Chinese patients with hepatocellular carcinoma. Curr Med Res Opin 2015; 31 (08) 1553-1560
    CrossrefPubMedGoogle Scholar
  • 63 Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer 2010; 116 (23) 5452-5460
    CrossrefPubMedGoogle Scholar
  • 64 Dong W, Zhang T, Wang ZG, Liu H. Clinical outcome of small hepatocellular carcinoma after different treatments: a meta-analysis. World J Gastroenterol 2014; 20 (29) 10174-10182
    CrossrefPubMedGoogle Scholar
  • 65 Jinhua H. RCT of TAE with simultaneously combined thermal ablation for large hepatocellular carcinoma (NCT02964260)
  • 66 Sohn W, Kang TW, Choi S-K. et al. Effect of oral antiviral treatment on long-term outcomes of radiofrequency ablation therapy for hepatitis B virus-related hepatocellular carcinoma. Oncotarget 2016; 7 (30) 47794-47807
    CrossrefPubMedGoogle Scholar
  • 67 ANRS collaborative study group on hepatocellular carcinoma (ANRS CO22 HEPATHER CC and CC cohorts). Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: Data from three ANRS cohorts. J Hepatol 2016; 65: 734-740
    CrossrefPubMedGoogle Scholar
  • 68 Kobayashi M, Suzuki F, Fujiyama S. et al. Sustained virologic response by direct antiviral agents reduces the incidence of hepatocellular carcinoma in patients with HCV infection. J Med Virol 2017; 89 (03) 476-483
    CrossrefPubMedGoogle Scholar
  • 69 Petta S, Cabibbo G, Barbara M. et al. Italian Liver Cancer (ITA.LI.CA) Group. Hepatocellular carcinoma recurrence in patients with curative resection or ablation: impact of HCV eradication does not depend on the use of interferon. Aliment Pharmacol Ther 2017; 45 (01) 160-168
    CrossrefPubMedGoogle Scholar
  • 70 Cabibbo G, Petta S, Calvaruso V. et al. Rete Sicilia Selezione Terapia - HCV (RESIST-HCV). Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. Aliment Pharmacol Ther 2017; 46 (07) 688-695
    CrossrefPubMedGoogle Scholar
  • 71 European Association for the Study of the Liver, . EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2018; 69 (01) 182-236
    CrossrefPubMedGoogle Scholar
  • 72 Cui J, Wang N, Zhao H. et al. Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma. Int J Cancer 2014; 134 (02) 342-351
    CrossrefPubMedGoogle Scholar
  • 73 Lee JH, Lee JH, Lim YS. et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology 2015; 148 (07) 1383-91.e6
    CrossrefPubMedGoogle Scholar
  • 74 Bruix J, Takayama T, Mazzaferro V. et al. STORM investigators. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol 2015; 16 (13) 1344-1354
    CrossrefPubMedGoogle Scholar